A rendering of Yingke Biopharma. [Photo/WeChat account: weigg6666]
The Fusidic acid cream product developed by Yingke Biopharma, located in China Medical City, Taizhou, Jiangsu province, has been approved for sale on the domestic market by the National Medical Products Administration.
This is another major step forward for by the company in the field of high-end formulation research and development, following the approval of Mopirocin ointment in April.
The Fusidic acid cream features efficient antibacterial activity and immunomodulatory effects, providing a new option for the treatment of certain skin infections.
The product features low drug resistance, strong permeability, and low allergenicity to precisely meet the core demands for improving efficacy and reducing the risk of side effects.
Founded in 2011, the company is a leading player in the subdivision of fat emulsions in China. Its products cover anesthesia, parenteral nutrition, oral solutions, and topical preparations.
The company expects to have 16 key varieties of medical products approved for retail sales within this year, with its product pipeline expected to enter a period of high activity.